Skip to main content
. 2022 Aug 24;9:949520. doi: 10.3389/fmed.2022.949520

TABLE 4.

Drug and non-drug allergens reported to cause SJS or TEN among reported cases from the literature.

Allergena Total (n = 1,059) SJS (n = 381) SJS-TEN Overlap (n = 76) TEN (n = 602) P-valueb
Drug Allergen
Antibiotics 285 (26.9) 84 (22.1) 20 (26.3) 181 (30.1) 0.022
 Sulfonamides 108 (10.2) 26 (6.8) 5 (6.6) 77 (12.8)
 Penicillins 60 (5.7) 21 (5.5) 6 (7.9) 33 (5.5)
 Quinolones 35 (3.3) 6 (1.6) 4 (5.2) 25 (4.2)
 Macrolides 25 (2.4) 12 (3.2) 1 (1.3) 12 (2.0)
 Vancomycin 21 (2.0) 2 (0.5) 2 (2.6) 17 (2.8)
 Tetracycline 11 (1.0) 4 (1.1) 1 (1.3) 6 (1.0)
 Other antibioticsa 72 (6.8) 19 (5.0) 5 (6.6) 48 (8.0)
Anticonvulsants 196 (18.5) 60 (15.7) 19 (25.0) 117 (19.4) 0.111
 Phenytoin 62 (5.7) 16 (4.2) 3 (3.9) 43 (7.1)
 Carbamazepine 54 (5.1) 15 (3.9) 8 (10.5) 31 (5.1)
 Lamotrigine 49 (4.6) 20 (5.2) 2 (2.6) 27 (4.5)
 Valproate 16 (1.5) 8 (2.1) 2 (2.6) 6 (1.0)
 Other anticonvulsants 32 (3.0) 10 (2.6) 5 (6.6) 17 (2.8)
Analgesics/anesthetics 126 (11.9) 34 (8.9) 14 (18.4) 78 (13.0) 0.031
 NSAIDs 93 (8.8) 24 (6.3) 9 (11.8) 60 (10.0)
  Ibuprofen 23 (2.2) 6 (1.6) 5 (6.6) 12 (2.0)
  Acetaminophen 24 (2.3) 5 (1.3) 3 (3.9) 16 (2.7)
 Analgesic/antipyretics, non-salicylate 37 (3.5) 10 (2.6) 6 (7.9) 21 (3.5)
 Other 5 (0.3) 1 (0.3) 1 (1.3) 3 (0.5)
Antineoplastics 119 (11.2) 42 (11.0) 10 (13.2) 67 (11.1) 0.858
 Systemic enzyme inhibitors (e.g., imatinib) 24 (2.3) 16 (4.2) 1 (1.3) 7 (1.2)
 Antimetabolites (e.g., methotrexate) 19 (1.8) 3 (0.8) 3 (3.9) 13 (2.2)
 Alkylating agents (e.g., cyclophosphamide) 15 (1.4) 3 (0.8) 1 (1.3) 11 (1.8)
 Immunotherapy checkpoint inhibitor combination (nivolumab) 12 (1.1) 4 (1.0) 0 (0) 8 (1.3)
 Immunomodulator agents (e.g., lenalidomide) 11 (1.0) 6 (1.6) 1 (1.3) 4 (0.7)
Other antineoplastics 50 (4.7) 12 (3.1) 4 (5.3) 34 (5.6)
Antiarthritics 48 (4.5) 14 (3.7) 6 (7.9) 28 (4.7) 0.265
 Xanthine oxidase inhibitors (allopurinol) 45 (4.2) 14 (3.7) 6 (7.9) 25 (4.2)
Antivirals 34 (3.2) 14 (3.7) 3 (3.9) 17 (2.8) 0.71
 HIV-specific antivirals (e.g., nevirapine) 25 (2.4) 12 (3.1) 0 (0) 13 (2.2)
Gastrointestinal drugs (e.g., sulfasalazine) 34 (3.2) 8 (2.1) 2 (2.6) 24 (4.0) 0.251
Psychotherapeutic drugs 25 (2.4) 12 (3.1) 1 (1.3) 12 (2.0) 0.419
 Antidepressant 11 (1.0) 6 (1.6) 0 (0) 5 (0.8)
Anti-Infectives 24 (2.3) 12 (3.1) 0 (0) 12 (2.0) 0.191
 Antimalarial drugs 20 (1.9) 11 (2.9) 0 (0) 9 (1.5)
Antifungals 20 (1.9) 7 (1.8) 0 (0) 13 (2.2) 0.426
Cardiovascular drugs 27 (2.5) 8 (2.1) 0 (0) 19 (3.2) 0.203
Diuretics 17 (1.6) 7 (1.8) 1 (1.3) 9 (1.5) 0.897
Vitamin/herb 15 (1.4) 8 (2.1) 0 (0) 7 (1.2) 0.267
Hormones 14 (1.3) 5 (1.3) 0 (0) 9 (1.5) 0.561
 Glucocorticoids 11 (1.0) 3 (0.8) 0 (0) 8 (1.3)
Biologicals/vaccine 10 (0.9) 6 (1.6) 1 (1.3) 3 (0.5) 0.222
Diagnostic (contrast medium) 10 (0.9) 3 (0.8) 2 (2.6) 5 (0.8) 0.287
Chemotherapy rescue/antidote agents 8 (0.8) 3 (0.8) 0 (0) 5 (0.8) 0.73
Antithrombotic agents 8 (0.8) 2 (0.5) 0 (0) 6 (1.0) 0.518
Cough/cold preparations 6 (0.6) 2 (0.5) 0 (0) 4 (0.7) 0.761
Immunosuppressants 6 (0.6) 5 (1.3) 0 (0) 1 (0.2) 0.052
Non-drug Allergen
Infection 68 (6.4) 51 (13.4) 2 (2.6) 15 (2.5) <0.001
 Mycoplasma pneumonia infection 44 (4.2) 38 (10.0) 2 (2.6) 4 (0.7)
Radiotherapy 27 (2.5) 11 (2.9) 2 (2.6) 14 (2.3) 0.861
Chemical substance 9 (0.8) 5 (1.3) 1 (1.3) 3 (0.5) 0.36
Others 25 (2.4) 4 (2.6) 1 (1.3) 20 (3.3)

NSAIDs, non-steroidal anti-inflammatory drugs; HIV, human immunodeficiency virus.

The number (percentage) in bold indicates a significant adjusted residual for that cell (meaning that there were significantly more or fewer cases than what would be expected by chance).

aThe detailed allergen included in each category could be found in the Tables 5, 6.

bP-values were provided based on Chi-square test for categorical variables.